ArticleEuropean radiology2026
Combination of dual-energy CT findings and clinical features predicts risk of frequent flares of gout.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision imaging biomarkers for gout: artifact-specific spectral CT parameters for personalized differentiation of tophi in a prospective study.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo develop and validate a model that integrates dual-energy computed tomography (DECT) and clinical features for the prediction of the risk of frequent gout flares (FrGF). MATERIALS AND
methodsThis retrospective cohort study included 1204 patients with gout who were randomly divided into training and validation cohorts and followed for 12 months after DECT. The patients were categorized into an FrGF group (≥ 2 flares, n = 606) and an infrequent gout flares (InGF) group (< 2 flares, n = 598) based on flare frequency during follow-up. Clinicoradiological features that were significant in univariate analysis were dimensionally reduced via least absolute shrinkage and selection operator regression, followed by multivariate logistic regression to identify independent risk factors for FrGF. An integrated clinicoradiological model was constructed using a nomogram. Model performance was evaluated using the receiver-operating characteristic (ROC) curve and clinical utility by decision curve analysis. The integrated model was compared with the clinical model using the DeLong test to evaluate the incremental value of radiological features.
resultsIndependent risk factors for FrGF were chronic arthritis, recurrent gout at baseline, intermittent medication, non-adherence to a low-purine diet, high monosodium urate burden, elevated Sharp/van der Heijde score, and tarsal bone erosion. The integrated model had an area under the ROC curve (AUC) of 0.95 (95% CI 0.92-0.97) in the validation cohort, outperforming the clinical model (AUC 0.83, 95% CI 0.79-0.87), demonstrating the incremental diagnostic value of DECT.
conclusionThe integrated model demonstrated excellent discriminative ability, calibration, and clinical value, enabling accurate prediction of the risk of FrGF. KEY POINTS: Question Frequent gout and infrequent gout differ in treatment strategies, but how can clinicians prospectively and accurately identify frequent gout? Findings Based on clinical and DECT features, this study identified 7 independent risk factors for frequent gout and developed and validated a predictive model. Clinical relevance This study's predictive model exhibits favorable predictive performance, and its web-based calculator helps clinicians assess the risk of frequent gout flares and predict clinical intervention efficacy, thus providing valuable evidence for formulating individualized clinical treatment plans.
Indexed as
Identifiers
41175200What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.